Kirjaudu sisään Inderes Free -tilillesi nähdäksesi kaikki sivun maksuton sisältö.

Luo ilmainen tunnus

Pharma Equity Group

0,103

DKK

−4,63 %

Alle 1K seuraajaa

PEG

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

−4,63%

+30,38%

−25,9%

−45,79%

−37%

−61,42%

−59,21%

−81,93%

−99,6%

Pharma Equity Group develops new medicines for the local treatment of serious and life-threatening inflammatory diseases for which there is currently no adequate treatment. The company uses repositioning of existing drugs and brings drug candidates to a clinical phase III stage, after which it is handed over to a strategic partner who will complete the development of the products and bring them to market, either independently or in collaboration with the company.

Markkina-arvo

126,44 milj. DKK

Vaihto

156,49 t. DKK

Liikevaihto

EBIT %

P/E -luku

Osinkotuotto %

Seuranta

Vastuuvapauslauseke

Claus Thestrup

CEO, Sweden

Viimeisimmät analyysit

Viimeisin analyysiraportti

Julkaistu: 31.03.2025

Pörssikalenteri

14.8.

2025

Osavuosikatsaus Q2'25

Kaikki

Analyysit

Webcastit

Tiedotteet

Kolmansien osapuolien sisällöt

NäytäKaikki sisältötyypit

Pörssitiedote28.5.2025 klo 8.29

Pharma Equity Group A/S Launches New Strategy to Drive Growth and Shareholder Returns

Pharma Equity Group

Pörssitiedote5.5.2025 klo 8.43

Passing of the General Meeting of Pharma Equity Group A/S

Pharma Equity Group

Pörssitiedote1.4.2025 klo 11.29

The Board of Directors' resolution on the issuance of convertible loans

Pharma Equity Group

Liity Inderesin yhteisöön

Älä jää mistään paitsi – luo käyttäjätunnus ja ota kaikki hyödyt irti Inderesin palvelusta.

FREE-tili

Pörssin suosituin aamukatsaus

Analyytikon kommentit ja suositukset

Osakevertailu

PREMIUM-tili

Kaikki yhtiöraportit ja sisällöt

Premium-työkalut (mm. sisäpiirin kaupat ja screeneri)

Mallisalkku

Luo ilmainen tunnus

Pharma Equity Group (One-pager): Proof-of-Concept year 2025

Analyysi31.3.2025 klo 14.16 -

Philip Coombes, Claus Thestrup

Pharma Equity Group (One-pager): Proof-of-Concept year 2025

Pharma Equity Group (One-pager): Proof-of-Concept year 2025

Pharma Equity Group

Pörssitiedote25.3.2025 klo 10.00

Notice convening the annual general meeting in Pharma Equity Group A/S

Pharma Equity Group

Kolmannen osapuolen analyysi24.3.2025 klo 9.13

Pharma Equity Group: Advanced Discussions with Prospective Licensing Partners - Analyst Group

Pharma Equity Group (“PEG” or “the Company”) has recently refined the Company’s execution strategy, prioritizing resources toward three key candidates, RNX-051, RNX-011, and RNX-041, where the Company identifies the shortest path to market and strong...

Pharma Equity Group

Kolmannen osapuolen analyysi21.3.2025 klo 5.53

Pharma Equity Group: Analyst Group Comments on PEG’s Year-End Report for 2024

Pharma Equity Group (“PEG” or “the Company”) published its Year-End report for 2024 on the 20th of March 2025.

Pharma Equity Group

Pörssitiedote20.3.2025 klo 7.03

Pharma Equity Group A/S - Annual Report 2024

Pharma Equity Group

Lehdistötiedote28.2.2025 klo 12.19

2025 Financial Calendar

Pharma Equity Group

Pörssitiedote28.2.2025 klo 11.56

Change of executive management and organizational change in Pharma Equity Group A/S

Pharma Equity Group

Lehdistötiedote14.1.2025 klo 9.06

Pharma Equity Group 2025 Financial Calendar

Pharma Equity Group

Kolmannen osapuolen analyysi13.12.2024 klo 14.16

Analyst Group Comment on Pharma Equity Group’s New Execution Strategy

Pharma Equity Group (“PEG” or “the Company”) announced on Friday, December the 13th, the board of directors’ decision on a new execution strategy and prioritization of clinical areas regarding the Company’s subsidiary Reponex Pharmaceuticals A/S (“Reponex...

Pharma Equity Group

Pörssitiedote13.12.2024 klo 11.21

The Board of Directors' decision on a new execution strategy and prioritisation of clinical areas in Reponex Pharmaceuticals A/S.

Pharma Equity Group

Pörssitiedote29.11.2024 klo 6.45

Martin Engell-Rossen will be Head of Cabinet to Denmark's new EU Commissioner Dan Jørgensen in Brussels and will therefore resign from the Board of Directors of Pharma Equity Group A/S

Pharma Equity Group

Kolmannen osapuolen analyysi19.11.2024 klo 11.26

Pharma Equity Group - Strengthened Balance Sheet Facilitates Continued Development - Analyst Group

Following the end of Q3-24, Pharma Equity Group (“PEG” or “the Company”) secured additional funding through a directed share issue, with a significant portion allocated to debt reduction. This strengthens the Company’s financial position, providing increased...

Pharma Equity Group

Pharma Equity Group: Opdatering fra interview med CEO Thomas K. Selsø

Analyytikon kommentti18.11.2024 klo 7.36 -

Pharma Equity Group: Opdatering fra interview med CEO Thomas K. Selsø

CEO Thomas K. Selsø opdatering fra selskabets netop aflagte Q3 regnskab

Pharma Equity Group

Kolmannen osapuolen analyysi15.11.2024 klo 11.55

Analyst Group Comments on PEG’s Q3 Report for 2024

Pharma Equity Group (“PEG” or “the Company”) published its Q3 report for 2024 on the 15th of November 2024.

Pharma Equity Group

Pörssitiedote15.11.2024 klo 7.32

Consolidated Interim report 1 January – 30 September 2024

Pharma Equity Group

Pharma Equity Group (One-pager): Capital position strenghtened

Analyysi28.10.2024 klo 15.41 -

Philip Coombes, Claus Thestrup

Pharma Equity Group (One-pager): Capital position strenghtened

At the start of Q4 on 04.10.2024, Pharma Equity Group further strengthened its capital base, raising DKK 51 million through a directed share issue

Pharma Equity Group

Kolmannen osapuolen analyysi23.10.2024 klo 10.08

Analyst Group Comment on Pharma Equity Group’s obtained patent protection in Japan for RNX-051

Pharma Equity Group (“PEG” or “the Company”) announced on Wednesday, October the 23rd, that the Company’s subsidiary Reponex Pharmaceuticals A/S (“Reponex”) has obtained patent protection in Japan for the treatment of colorectal cancer with RNX-051, ...

Pharma Equity Group

Inderesin vastuuvapauslauseke löytyy täältä. Kunkin Inderesin aktiivisessa seurannassa olevan osakkeen tarkemmat tiedot löytyvät kunkin osakkeen omilta yhtiösivuilta Inderes-sivustolla. © Inderes Oyj. Kaikki oikeudet pidätetään.